13F HOLDINGS REPORT (Amended)
MPM ASSET MANAGEMENT LLC
Quarter ended Q3 2023 · Filed September 7, 2023 · Accession 0000950123-23-008457
Total Value
$203.9M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Entrada Therapeutics, Inc. | TRDA | 4,425,784 | $67.0M | 32.86% |
| 2 | Dyne Therapeutics, Inc. | DYN | 4,951,303 | $55.7M | 27.32% |
| 3 | iTeos Therapeutics, Inc. | 46565G104 | 2,738,785 | $36.3M | 17.78% |
| 4 | Repare Therapeutics, Inc. | 760273102 | 2,242,636 | $23.7M | 11.64% |
| 5 | Werewolf Therapeutics, Inc. | HOWL | 4,284,172 | $13.1M | 6.41% |
| 6 | Adaptimmune Therapeutics plc | ADTI | 6,287,101 | $5.8M | 2.85% |
| 7 | Harpoon Therapeutics, Inc. | 41358P106 | 3,131,388 | $2.2M | 1.09% |
| 8 | Oncorus, Inc. | 68236R103 | 2,849,464 | $115,403 | 0.06% |